BRAFV600-mutant melanomas are exquisitely sensitive to BRAF inhibitors such as dabrafenib and vemurafenib, which alone or in combination with a MEK inhibitor improve the overall survival of BRAFV600-mutant melanoma patients [7-10]. The gene discussed is MAP2K7; the disease is melanoma.